FDA drug information that never reaches clinicians [1]

New England Journal of Medicine

Volumn 362, Issue 6, 2010, Pages 561-563

  Hohneker, John ^a   Ericson, Solveig ^a   Gruia, Gabriela ^a  

^a Novartis Pharmaceuticals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID; CERIVASTATIN; CYTOCHROME P450; HEME; ILOPERIDONE; IXABEPILONE; MIBEFRADIL; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

CAUSE OF DEATH; CLINICAL TRIAL; DECISION MAKING; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCALCEMIA; LETTER; MORTALITY; NEPHROTOXICITY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; CLINICAL STUDY; IN VITRO STUDY; RISK; CHEMICALLY INDUCED DISORDER; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; KIDNEY DISEASE; NOTE; UNITED STATES; DRUG EFFECT; DRUG INTERACTION; INFORMATION DISSEMINATION; LEGAL ASPECT;

DIPHOSPHONATES; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KIDNEY DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; INFORMATION DISSEMINATION;

EID: 76649084268     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0911892     Document Type: Letter

References (2)

1. Schwartz LM, Woloshin S. Lost in transmission - FDA drug information that never reaches clinicians. N Engl J Med 2009; 361:1717-20.
2. Drugs@FDA. Approval history of NDA 021223: Zometa. Silver Spring, MD: Food and Drug Administration. (Accessed January 21, 2010, at http://www.accessdata.fda.gov/Scripts/cder/ DrugsatFDA/index.cfm?fuseaction= Search.Label- ApprovalHistory#apphist.)